Még nem toboroz
A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.
2026-525161-40-00· 2. fázis· PannTheraPi· Forrás
Még nem toboroz
A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.
2026-525162-21-00· 2. fázis· PannTheraPi· Forrás
Még nem toboroz
Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial
2026-526632-39-00· 3. fázis· Les Hopitaux Universitaires De Strasbourg· Forrás
Még nem toboroz
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· 3. fázis· Fondation A De Rothschild· Forrás
Toboroz
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· 3. fázis· UCB Biopharma SRL· Forrás
Toboroz
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
2024-519133-29-00· 2. fázis· Fondation A De Rothschild· Forrás
Toboroz
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
2025-524894-17-00· 2/3. fázis· Eyebiotech Limited· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· 3. fázis· UCB Biopharma SRL· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
Assessment of the Clinical and Economic Impact of Sim&Size, a Simulation Software for Implantable Devices Used in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study.
NCT07433075· Sim&Cure· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· 3. fázis· Sanofi· Forrás
Toboroz
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065· 3. fázis· AbbVie· Forrás
Toboroz
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)
2024-519521-37-01· 2/3. fázis· Corxel Pharmaceuticals Co. Ltd.· Forrás
Toboroz
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Efficacy and Safety of Tran Cannula in Combined Pseudoexfoliative Glaucoma and Cataract Surgery Compared With Augmented Ocular Irrigation
NCT06979752· Hôpital Privé de la Baie· Forrás
Fut, nem toboroz
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· 2/3. fázis· EyeBiotech Ltd.· Forrás
Még nem toboroz
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
NCT06663189· 3. fázis· University Hospital, Strasbourg, France· Forrás
Fut, nem toboroz
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· 2/3. fázis· Eyebiotech Limited· Forrás
Fut, nem toboroz
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· 3. fázis· argenx· Forrás
Toboroz
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
NCT06370182· Anaconda Biomed S.L.· Forrás
Toboroz
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587· 3. fázis· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Forrás
Toboroz
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
NCT05476991· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Meghívásos bevonás
An Open-label Study of XEN1101 in Epilepsy
NCT05718817· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Toboroz
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Toboroz
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Toboroz
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Stenting Versus Neurosurgical Treatment of Idiopathic Intracranial Hypertension.
NCT05050864· Fondation Ophtalmologique Adolphe de Rothschild· Forrás
Fut, nem toboroz
LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment
NCT04999423· Microvention-Terumo, Inc.· Forrás
Toboroz
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke
NCT05105633· 2/3. fázis· University of Melbourne· Forrás
Fut, nem toboroz
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
NCT04657289· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
RESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy
NCT04451278· Fondation Ophtalmologique Adolphe de Rothschild· Forrás
Fut, nem toboroz
Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment
NCT04034810· Balt Extrusion· Forrás
Fut, nem toboroz
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
NCT03981003· Centre Hospitalier Universitaire de Nīmes· Forrás
Toboroz
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
OFSEP High Definition Cohort
NCT03603457· EDMUS Foundation· Forrás
Toboroz
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
NCT03267459· Fondation Ophtalmologique Adolphe de Rothschild· Forrás